Conditions: Chronic Hepatitis C
Keywords: Chronic Hepatitis C Protease Inhibitor
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: MP-424 (Telaprevir)
Intervention descriptions: intervention 1: Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)

Protocol document: